PRRT2 and malignant colon neoplasm: Collectively, as summarized in the working model shown in Fig 4D, our findings using highly selective agonists and inhibitors provide evidence that activating M3R, PKC, or p38 MAPK increases the levels of selected microRNAs—miR-21, miR-221, and miR-222—in human colon cancer cells.